Retatrutide (LY3437943) is a novel triple-hormone receptor agonist developed by Eli Lilly and currently in Phase 3 clinical trials. It simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple mechanism distinguishes it from all currently approved anti-obesity medications and makes it the most mechanistically comprehensive compound in its class.
Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP dual agonist), retatrutide’s additional glucagon receptor activation adds a thermogenic dimension — directly increasing energy expenditure and hepatic fat oxidation. Researchers studying metabolic syndrome, obesity pathways, and the next generation of GLP-based compounds have cited retatrutide as the most significant development in this space since tirzepatide.
Published Phase 2 data in the New England Journal of Medicine (2023) established retatrutide’s efficacy profile:
The dose-response relationship was clear — higher doses produced greater weight reduction, with the 12mg group showing the most dramatic results. Importantly, the weight loss curve had not plateaued by week 48 in the highest-dose group, suggesting continued efficacy potential beyond the trial period.
Understanding how retatrutide produces greater weight reduction than its predecessors requires understanding each receptor’s contribution:
GLP-1 receptor activation reduces appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion. This is the same mechanism as semaglutide and is the foundational component of all GLP-based compounds.
GIP receptor activation enhances the insulinotropic response and contributes to additional appetite suppression. This is the mechanism tirzepatide added over semaglutide, accounting for the ~6% additional weight loss seen with tirzepatide.
This is retatrutide’s distinguishing feature. Glucagon receptor activation increases energy expenditure through thermogenesis and directly stimulates hepatic fat oxidation. This adds a fat-burning component that GLP-1 and GIP agonism alone do not produce, which explains the additional weight reduction beyond tirzepatide.
| Compound | Receptors | Avg Weight Loss | Status (2026) |
|---|---|---|---|
| Semaglutide | GLP-1 | ~14.9% | FDA Approved |
| Tirzepatide | GLP-1 + GIP | ~20.9% | FDA Approved |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24.2% | Phase 3 Trials |
The Phase 2 trial used a gradual dose escalation to minimize gastrointestinal side effects:
Note: This dosage information is derived from published clinical trial data and is provided for research reference only. Not for clinical or personal use.
The most commonly reported side effects in Phase 2 research were gastrointestinal and dose-dependent:
Gastrointestinal effects typically diminished after stabilization at each dose level. Serious adverse events were rare. The gradual escalation protocol was specifically designed to minimize these effects.
As of 2026, retatrutide is not FDA-approved and is not available by prescription. Researchers access it through two primary pathways:
Licensed research peptide suppliers stock retatrutide as a research compound for laboratory use. When sourcing, prioritize suppliers that provide:
Peptides For Sale stocks research-grade Retatrutide 12mg with full third-party CoA documentation and 99%+ purity. For laboratory and research use only.
Eli Lilly’s Phase 3 trials are currently enrolling. Search ClinicalTrials.gov for “retatrutide” or NCT05952726 to find active trials near you. Participants receive the compound at no cost under medical supervision.
According to Ahrefs data, “retatrutide peptide” went from approximately 2,400 monthly searches in May 2024 to over 238,000 in early 2026 — a 100x increase in 24 months. The combined traffic potential of the retatrutide keyword cluster exceeds 420,000 monthly searches, reflecting the extraordinary level of research and public interest in this compound.
Retatrutide (LY3437943) is not FDA-approved for any indication as of 2026. All information in this article is for educational and research reference purposes only. This is not medical advice. Research peptides are for laboratory and research use only and are not intended for human consumption.
